Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia Patients

ConditionChronic Myeloid Leukemia

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

AgeNot listed

SponsorAssiut University

About this trial

to known the impact of drugs that used in CML pt as TKIs on glucose and lipid metabolism

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

CML patients free medical history

Disqualifiers

diabetic

Trial population

CML patients

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Tyrosine kinase Inhibitors (Imatinib & Nilotinib)
Drug
these drugs used in CML only

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

Change in HbA1c levels in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

Assessment of change in HbA1c levels in CML patients treated with TKIs.

Time frame

Baseline and 3, 6, 9, and 12 months

Secondary outcomes

Change in lipid profile in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

Assessment of changes in lipid profile including total cholesterol, triglycerides, LDL, and HDL in CML patients treated with TKIs.

Time frame

Baseline and 3, 6, 9, and 12 months

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assiut University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: